Alkermes (NASDAQ:ALKS) Stock: Insider David Joseph Gaffin Sells 2,035 Shares

Alkermes plc (NASDAQ:ALKS) EVP David Gaffin sold 2,035 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total value of $93,955.95. Following the transaction, the executive vice president owned 219,353 shares of the company’s stock, valued at approximately $10,127,528.01. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Joseph Gaffin also recently made the following trade(s):

• On Friday, October 2nd, David Gaffin sold 2,034 shares of Alkermes stock. The stock was sold at an average price of $41.03, for a total transaction of $83,455.02.
• On Thursday, September 3rd, David Gaffin sold 2,034 shares of Alkermes stock. The stock was sold at an average price of $48.01, for a total transaction of $97,652.34.

Alkermes Stock Performance

Shares of ALKS stock opened at $45.89 on Thursday. The stock has a market cap of $7.70 billion, a PE ratio of 1,523.00 and a beta of 0.32. The company has a current ratio of 2.47, a quick ratio of 1.85 and a debt-to-equity ratio of 0.79. Alkermes plc has a 12 month low of $27.00 and a 12 month high of $55.67. The company’s fifty day moving average price is $43.86 and its 200-day moving average price is $40.66.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.17. The business had revenue of $480.13 million during the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a negative net margin of 0.02% and a positive return on equity of 0.40%. The business’s revenue for the quarter was up 21.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.49 earnings per share. On average, equities analysts expect that Alkermes plc will post -0.57 EPS for the current fiscal year.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Alkermes reported third-quarter EPS of $0.09, versus analysts’ expectation of a $0.08 loss, and revenue of $480.1 million, ahead of the $463.5 million consensus and up 21.8% year over year. Article: Alkermes Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its price target from $56 to $57 and maintained an outperform rating, signaling continued analyst confidence. Royal Bank of Canada ratings
• Positive Sentiment: The company reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton around mid-2027, offering a defined pipeline milestone. Article: Alkermes reiterates sales outlook and Phase III timing
• Neutral Sentiment: HC Wainwright lifted its target from $43 to $50 but kept a neutral rating, reflecting a higher valuation estimate without a more bullish recommendation. HC Wainwright ratings
• Neutral Sentiment: EVP David Gaffin sold 2,035 shares, about 0.92% of his holdings. The transaction was made under a pre-arranged Rule 10b5-1 plan, making it less indicative of a fresh change in his outlook. Article: Insider share sale
• Negative Sentiment: Despite the beat, third-quarter profit was reported at $16 million and EPS fell from $0.49 a year earlier. A separate analysis also raised concerns that the shares may be overvalued following the ALKS 7290 trial launch. Article: Lower Q3 profit Article: Valuation concerns

Analyst Upgrades and Downgrades

Several research analysts recently commented on ALKS shares. JPMorgan Chase & Co. raised their price target on shares of Alkermes from $60.00 to $61.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Truist Financial started coverage on Alkermes in a research report on Friday, October 16th. They set a “buy” rating and a $55.00 price target for the company. HC Wainwright lifted their price objective on Alkermes from $43.00 to $50.00 and gave the company a “neutral” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and set a $65.00 target price (up from $43.00) on shares of Alkermes in a research report on Tuesday, July 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 price target on shares of Alkermes in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $55.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ALKS. Baird Financial Group Inc. bought a new stake in Alkermes during the second quarter worth approximately $2,791,000. S&CO Inc. acquired a new position in Alkermes during the second quarter valued at $12,824,000. Quantinno Capital Management LP boosted its position in Alkermes by 131.1% during the 1st quarter. Quantinno Capital Management LP now owns 44,932 shares of the company’s stock worth $1,589,000 after acquiring an additional 25,492 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in Alkermes during the 2nd quarter worth about $2,479,000. Finally, Seven Fleet Capital Management LP purchased a new position in Alkermes during the 1st quarter valued at about $855,000. 95.21% of the stock is owned by institutional investors and hedge funds.

About Alkermes

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.